Abstract
Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
